

## Pressure BioSciences, Inc. to Discuss First Quarter 2009 Financial Results and Provide Business Update

SOUTH EASTON, Mass., May 20, 2009 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (Nasdaq:PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to discuss its Q1 2009 financial results and to provide a business update. Anyone interested may listen to the teleconference either by telephone or through a live web-cast. The teleconference and web-cast information is provided below:

```
Date: Thursday, May 21, 2009
Time: 4:15 p.m. Eastern Daylight Time (EDT)
```

To attend this teleconference via web-cast, please visit the Company's website at <a href="https://www.pressurebiosciences.com">www.pressurebiosciences.com</a>.

To attend this teleconference via telephone, please use the following dial-in information:

```
Tel: (877) 646-2366
Conference ID: 11088895
```

For those unable to participate in the live teleconference, a replay will be available approximately one hour after the call ends through June 21, 2009, and will be accessible through the Company's website.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 6 foreign patents covering multiple applications of PCT in the life sciences field, including genomic and proteomic sample preparation, pathogen inactivation, the control of chemical (primarily enzymatic) reactions, immunodiagnostics, and protein purification. PBI currently focuses its efforts in the development and sale of PCT-enhanced enzymatic digestion products designed specifically for the mass spectrometry marketplace, as well as sample preparation products for biomarker discovery, soil and plant biology, forensics, histology, and counter-bioterror applications.

```
CONTACT: Pressure BioSciences, Inc.
Investor Contacts:
Richard T. Schumacher, President & CEO
```

Joseph Damasio, Jr., Controller 508-230-1828